Company profile CKPT
After 39 days of this quarter the interest is at 157.0. Based on that we can calculate that during remaining 52 days it will total up to 366.0. Checkpoint Therapeutics expected interest is significantly higher compared to previous quarter (+102.2%) and same quarter last year (+202.5%).
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 9 | 59 555.6% QoQ | 64 8.5% QoQ | 87 35.9% QoQ |
| 2020 | 51 466.7% YoY -41.4% QoQ | 61 3.4% YoY 19.6% QoQ | 216 237.5% YoY 254.1% QoQ | 54 -37.9% YoY -75.0% QoQ |
| 2021 | 288 464.7% YoY 433.3% QoQ | 210 244.3% YoY -27.1% QoQ | 115 -46.8% YoY -45.2% QoQ | 98 81.5% YoY -14.8% QoQ |
| 2022 | 138 -52.1% YoY 40.8% QoQ | 122 -41.9% YoY -11.6% QoQ | 116 0.9% YoY -4.9% QoQ | 94 -4.1% YoY -19.0% QoQ |
| 2023 | 121 -12.3% YoY 28.7% QoQ | 132 8.2% YoY 9.1% QoQ | 138 19.0% YoY 4.5% QoQ | 181 92.6% YoY 31.2% QoQ |
| 2024 | 157 29.8% YoY -13.3% QoQ | - | - | - |
The average 5 years interest of Checkpoint Therapeutics was 9.62 per week. The last year interest of Checkpoint Therapeutics compared to the last 5 years has changed by 35.14%. This is something to be checked. The last year interest is quite higher compared to 5 years ago. It has increased by 177.19%.
After 34 days of this quarter the interest is at 0.0. Based on that we can calculate that during remaining 58 days it will total up to 0.0. That appears to be equal to previous quarter and same quarter last year.
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2018 | - | - | - | 57 |
| 2019 | 281 393.0% QoQ | 71 -74.7% QoQ | 60 -15.5% QoQ | 30 -47.4% YoY -50.0% QoQ |
| 2020 | 69 -75.4% YoY 130.0% QoQ | 172 142.3% YoY 149.3% QoQ | 0 -100.0% YoY -100.0% QoQ | 0 -100.0% YoY -100.0% QoQ |
| 2021 | 0 -100.0% YoY -100.0% QoQ | 0 -100.0% YoY -100.0% QoQ | 0 -100.0% YoY -100.0% QoQ | 0 -100.0% YoY -100.0% QoQ |
| 2022 | 0 -100.0% YoY -100.0% QoQ | 0 -100.0% YoY -100.0% QoQ | 0 -100.0% YoY -100.0% QoQ | 0 -100.0% YoY -100.0% QoQ |
| 2023 | 0 -100.0% YoY -100.0% QoQ | 0 -100.0% YoY -100.0% QoQ | 0 -100.0% YoY -100.0% QoQ | 0 -100.0% YoY -100.0% QoQ |
The average 5 years interest of Cosibelimab was 2.84 per week. The last year interest of Cosibelimab compared to the last 5 years has changed by -100.0%. This is something to be checked. The last year interest is quite lower compared to 5 years ago. It has decreased by -100.0%.
Google Trends for Checkpoint Therapeutics clinical trials
Not enough data for reliable calculations!
There is not enough data for Checkpoint Therapeutics clinical trials to provide analysis
There is not enough data for Checkpoint Therapeutics clinical trials to provide correlation calculation
There is not enough data for Checkpoint Therapeutics clinical trials to provide analysis
There is not enough data for CK-302 immunotherapy to provide analysis
There is not enough data for CK-302 immunotherapy to provide correlation calculation
There is not enough data for CK-302 immunotherapy to provide analysis
There is not enough data for Olafertinib lung cancer to provide analysis
There is not enough data for Olafertinib lung cancer to provide correlation calculation
There is not enough data for Olafertinib lung cancer to provide analysis
There is not enough data for CK-103 target therapy to provide analysis
There is not enough data for CK-103 target therapy to provide correlation calculation
There is not enough data for CK-103 target therapy to provide analysis
There is not enough data for Anti-CAIX antibody to provide analysis
There is not enough data for Anti-CAIX antibody to provide correlation calculation
There is not enough data for Anti-CAIX antibody to provide analysis
After 39 days of this quarter the interest is at 55.0. Based on that we can calculate that during remaining 52 days it will total up to 128.0. Checkpoint Therapeutics stock expected interest is significantly higher compared to previous quarter (+54.2%) but similar to same quarter last year.
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 68 | 140 105.9% QoQ | 141 0.7% QoQ | 34 -75.9% QoQ |
| 2020 | 98 44.1% YoY 188.2% QoQ | 74 -47.1% YoY -24.5% QoQ | 280 98.6% YoY 278.4% QoQ | 195 473.5% YoY -30.4% QoQ |
| 2021 | 384 291.8% YoY 96.9% QoQ | 250 237.8% YoY -34.9% QoQ | 221 -21.1% YoY -11.6% QoQ | 182 -6.7% YoY -17.6% QoQ |
| 2022 | 206 -46.4% YoY 13.2% QoQ | 151 -39.6% YoY -26.7% QoQ | 210 -5.0% YoY 39.1% QoQ | 26 -85.7% YoY -87.6% QoQ |
| 2023 | 158 -23.3% YoY 507.7% QoQ | 38 -74.8% YoY -75.9% QoQ | 158 -24.8% YoY 315.8% QoQ | 83 219.2% YoY -47.5% QoQ |
| 2024 | 55 -65.2% YoY -33.7% QoQ | - | - | - |
The average 5 years interest of Checkpoint Therapeutics stock was 12.08 per week. The last year interest of Checkpoint Therapeutics stock compared to the last 5 years has changed by -24.42%. This is something to be checked. The last year interest is quite higher compared to 5 years ago. It has increased by 15.57%.
After 39 days of this quarter the interest is at 87.0. Based on that we can calculate that during remaining 52 days it will total up to 203.0. Checkpoint Therapeutics news expected interest is significantly higher compared to previous quarter (+420.5%) and same quarter last year (+103.0%).
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 27 | 26 -3.7% QoQ | 0 -100.0% QoQ | 0 -100.0% QoQ |
| 2020 | 99 266.7% YoY inf% QoQ | 256 884.6% YoY 158.6% QoQ | 183 inf% YoY -28.5% QoQ | 63 inf% YoY -65.6% QoQ |
| 2021 | 133 34.3% YoY 111.1% QoQ | 156 -39.1% YoY 17.3% QoQ | 34 -81.4% YoY -78.2% QoQ | 42 -33.3% YoY 23.5% QoQ |
| 2022 | 116 -12.8% YoY 176.2% QoQ | 133 -14.7% YoY 14.7% QoQ | 40 17.6% YoY -69.9% QoQ | 98 133.3% YoY 145.0% QoQ |
| 2023 | 100 -13.8% YoY 2.0% QoQ | 69 -48.1% YoY -31.0% QoQ | 276 590.0% YoY 300.0% QoQ | 39 -60.2% YoY -85.9% QoQ |
| 2024 | 87 -13.0% YoY 123.1% QoQ | - | - | - |
The average 5 years interest of Checkpoint Therapeutics news was 7.57 per week. The last year interest of Checkpoint Therapeutics news compared to the last 5 years has changed by 28.53%. This is something to be checked. The last year interest is quite higher compared to 5 years ago. It has increased by 575.69%.
There is not enough data for Checkpoint Therapeutics contact to provide analysis
There is not enough data for Checkpoint Therapeutics contact to provide correlation calculation
There is not enough data for Checkpoint Therapeutics contact to provide analysis